Fennec Pharmaceuticals Inc. (TSE:FRX) Senior Officer Adrian J. Haigh Acquires 22,222 Shares

Fennec Pharmaceuticals Inc. (TSE:FRX) Senior Officer Adrian J. Haigh bought 22,222 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The shares were purchased at an average cost of C$2.31 per share, with a total value of C$51,332.82.

Fennec Pharmaceuticals Trading Up 0.8 %

Fennec Pharmaceuticals stock opened at C$14.32 on Wednesday. The company has a quick ratio of 10.17, a current ratio of 3.29 and a debt-to-equity ratio of 881.09. Fennec Pharmaceuticals Inc. has a 52 week low of C$9.27 and a 52 week high of C$15.43. The company has a market capitalization of C$387.21 million, a price-to-earnings ratio of -14.04 and a beta of 0.35. The stock has a 50-day moving average price of C$13.50 and a 200 day moving average price of C$12.59.

Fennec Pharmaceuticals (TSE:FRX) last issued its quarterly earnings results on Thursday, March 21st. The biopharmaceutical company reported C($0.14) EPS for the quarter, missing the consensus estimate of C$0.02 by C($0.16). Fennec Pharmaceuticals had a negative return on equity of 1,005.59% and a negative net margin of 75.50%. The firm had revenue of C$13.25 million for the quarter, compared to analysts’ expectations of C$12.88 million. Sell-side analysts anticipate that Fennec Pharmaceuticals Inc. will post 0.4202312 EPS for the current year.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.